By: Shu Xiang, Mittal Consulting

On June 15, 2026, the FDA issued a warning letter to Happiest Baby, Inc., the manufacturer of SNOO Smart Sleeper. For companies that view regulatory as a one-time effort to obtain the FDA’s blessing and then move on, this warning letter is a clear wake-up call.

If you’ve been a new parent in the last decade, chances are you’ve either used or heard of the SNOO. The smart bassinet secures the baby with an attached sleep sack, and automatically rocks the baby when crying is sensed. Since its launch in 2016, SNOO has quickly become a commercial success among sleep-deprived and safety-conscious new parents. Four years later, SNOO began its FDA regulatory journey, receiving Breakthrough Designation in 2020 and De Novo authorization in 2023 for facilitating supine sleep for infants under 6 months of age who are not yet able to roll over consistently.

The Importance of Post market Design Control

The non-compliances cited in the SNOO warning letter include failure to submit new marketing applications for product dimension changes, intended use environment changes, and failures to meet quality management system (QMS) requirements.

A primary citation in SNOO’s warning letter was that the company did not fulfill its regulatory and quality management duties in design control. While the product’s original marketing application included three sizes (S, M, L) of the attached sleep sack, the company has since introduced two additional sizes (XS and XL). Notably, the XS size extends the use to babies weighing one pound less than the minimum weight in the FDA-authorized labeling.

For a consumer product, these are innocent, incremental product improvements in response to customer feedback. For a medical device company, these represent design changes that impact the product risk profile. These design changes typically require (1) validation testing and (2) a new marketing application, even if the changes may be intended to improve safety or effectiveness. Neither of which the SNOO manufacturer did.

The Consumer Product to Medical Device Regulatory Strategy

If a medical device is subjected to heavy regulatory scrutiny, why does a company pursue FDA authorization when its product is already wildly successful in the consumer space?

In a fiercely competitive market with a premium brand image to maintain, SNOO needed strong marketing claims to differentiate from hundreds of other smart bassinets. While FDA states that current scientific evidence does not support device claims about preventing sudden infant death syndrome (SIDS), a claim about facilitating supine sleep indirectly associates the product with the potential to reduce SIDS risk, which is still attractive to parents. In addition, by establishing a regulatory precedent, SNOO raises the bar for any competitors seeking to make similar claims.

For a well-funded company with years of real-world data to support a marketing submission to FDA, pursuing FDA authorization could create a competitive moat. However, as seen in SNOO’s case, this strategy requires long-term efforts to execute.

A Lesson for Everyone: Getting through the Door is Just the First Step

Obtaining the FDA’s marketing authorization is not a one-and-done exercise; it commits a company to ongoing regulatory compliance and quality management over the entire product lifecycle. Just like the profession of law, passing the bar exam allows you to practice, but from that day forward, you are held up to the rules of professional conduct. Without sustained commitment to regulatory and quality management, even a great strategy with a well-executed submission can create long-term compliance challenges.

In SNOO’s case, when a consumer product QMS, often ISO 9001-based, transitions to an ISO 13485-based medical device QMS, the focus shifts from mere customer satisfaction to safety and effectiveness. This is not just a change in procedures; it is a fundamental shift in mindset and culture for everyone, from top management to front-line workers. Driving and sustaining that shift requires continuous, long-term quality and regulatory support.

An important lesson for anyone going down an FDA pathway—regulatory success does not end with the FDA nod. In the long postmarket journey, internal or strategic partnerships with external regulatory and quality expertise is crucial.

It is a marathon, not a sprint.